Jasper Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Jasper Therapeutics

11/08/2023 22:06

* Jasper Therapeutics Inc  JSPR.OQ  reported a quarterly
adjusted
loss of 15 cents​​ per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 15 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Jasper Therapeutics Inc's reported EPS for the quarter was
a
loss of 15 cents​.
    * The mean earnings estimate of analysts had fallen by
about 12.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Jasper Therapeutics Inc shares had risen by 2.9% this
quarter and gained 192.0% so far this year.
    * The company reported a quarterly loss of $16.08 million.
    * Wall Street's median 12-month price target for Jasper
Therapeutics Inc is $6.85 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 11 at 09:06 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.15          -0.15          Met
 Mar. 31 2023      -0.16          -0.16          Met
 Dec. 31 2022      -0.36          -0.36          Met
 Sep. 30 2022      -0.34          -0.32          Beat